Covid-19 roundup: NIH spotlights blood thinners in its next big trial; All it took was a pandemic to get JPM out of SF
After immune modulators and antibodies, blood thinners are the next class of drugs to be put through a Phase III trial organized under the NIH’s ACTIV initiative.
Three different anticoagulants have been named for the master protocol: heparin, aspirin and apixaban. Informed by studies suggesting that many patients who died from Covid-19 have formed unusual blood clots throughout their bodies — including in their smallest blood vessels — the NIH wants to see which therapies are the most effective at preventing or reducing them and thus improving outcomes for patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.